Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

266
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
266
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

390
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
390
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

201
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
201
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

414
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
414
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

293
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
293
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formulation and Evaluation of Indomethacin Nanosuspensions Stabilized by Poly(2-oxazine) and Poly(2-oxazoline)-Based Polymers for Solubility Enhancement.

Pharmaceutical research·2026
Same author

Potential of Low-Frequency Raman Spectroscopy for Structural Screening of Lipid-Based Drug Delivery Systems for Poorly Water-Soluble Drugs.

Molecular pharmaceutics·2026
Same author

Unexpected Effect of Digestion Products of Infant Formula in Enhancing the Solubilisation of Tolfenamic Acid During Digestion.

Pharmaceutics·2026
Same author

Nanoparticle-based approaches to improve the treatment of middle and external ear infections.

Expert opinion on drug delivery·2026
Same author

Co-administering clofazimine with infant formula enhances its oral bioavailability in rats and pigs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2025
Same author

The use of nanocarriers for the treatment of <i>Candida auris</i> infections.

Expert opinion on drug delivery·2025
Same journal

Design and Optimization of Beta-Caryophyllene Nanoemulgel for Enhanced Antihyperlipidemic Activity: A Response Surface Approach.

Current drug delivery·2026
Same journal

Optimization of Andrographolide Nanocrystal-loaded Liposomes by Box-Behnken Design and its <i>In vitro</i> and <i>In vivo</i> Evaluation.

Current drug delivery·2026
Same journal

Development and Assessment of Rutin/Betamethasone-Loaded PAN-PVP Nanofibers for Wound Healing Applications.

Current drug delivery·2026
Same journal

QbD-Driven Rational Design of Vancomycin-Loaded Nanocubosome <i>In situ</i> Ocular Gels: Augmenting Precorneal Retention and Improving Anti-MRSA Keratitis Treatment.

Current drug delivery·2026
Same journal

Curcumin-based Nanotherapeutics to Combat Neurodegenerative Disease: Drug Delivery Strategies and Therapeutic Potential.

Current drug delivery·2026
Same journal

Corrigendum to: Nanoparticle-Mediated Transcytosis in Tumor Drug Delivery: Mechanisms, Categories, and Novel Applications.

Current drug delivery·2026
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.7K

Confectionery-based dose forms.

Kristian J Tangso, Quy Phuong Ho, Ben J Boyd1

  • 1Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus) 381 Royal Parade, Parkville, Victoria. ben.boyd@monash.edu.

Current Drug Delivery
|August 23, 2014
PubMed
Summary
This summary is machine-generated.

Novel confectionery-based dosage forms like medicated chewing gums and lollipops offer improved patient compliance. These unconventional options provide new avenues for oral and systemic drug delivery, especially for specific patient groups.

More Related Videos

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.4K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.7K
Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.4K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.3K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Formulation Development

Background:

  • Traditional dosage forms (tablets, capsules, syrups) face challenges with patient adherence.
  • Growing market demand and patient preferences necessitate exploration of alternative drug delivery methods.
  • Confectionery-based dosage forms present a promising solution to enhance patient compliance.

Purpose of the Study:

  • To review existing unconventional dosage forms, focusing on confectionery-based options.
  • To highlight medicated chewing gums, medicated lollipops, and oral bioadhesive devices.
  • To explore their application in oral cavity treatment and systemic drug delivery.

Main Methods:

  • Literature review of available unconventional dosage forms.
  • Analysis of confectionery-based drug delivery systems.
  • Focus on medicated gums, lollipops, and oral bioadhesives for drug administration.

Main Results:

  • Confectionery-based dosage forms demonstrate significant potential for improving patient compliance.
  • Medicated chewing gums, lollipops, and oral bioadhesive devices are viable unconventional delivery systems.
  • These forms are suitable for both local oral treatment and systemic drug absorption.

Conclusions:

  • Innovative confectionery-based dosage forms offer a valuable alternative to conventional methods.
  • There is a significant opportunity for formulators to develop new products in this area.
  • These novel forms are particularly beneficial for atypical patient populations requiring improved adherence.